Stanford University
To use a consistent and standardized platform to retrospectively and prospectively study children and young adults with B cell malignancies receiving Immunotherapy, blinatumomab and/or inotuzumab ozogamicin.
Lymphoid Leukemia
Questionnaire for patients receiving therapy
Study Type : | Observational |
Estimated Enrollment : | 500 participants |
Official Title: | Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy |
Actual Study Start Date : | August 30, 2024 |
Estimated Primary Completion Date : | August 30, 2024 |
Estimated Study Completion Date : | August 30, 2024 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | to 26 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Stanford University
Palo Alto, California, United States, 94305